 |
ViroPharma To Participate In Two May Healthcare Investor Conferences
May 9, 2013
|
14.1 KB |
|
| |
EXTON, Pa., May 9, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Robert Doody, director of investor relations, will present at the 2013 Bank of America Merrill Lynch Healthcare Conference at 11:20 AM PT (2:20 PM ET) on Tuesday, May 14, 2013. The conference is being held at the Encore at the Wynn Hotel in Las Vega...
|
|
ViroPharma Announces First Quarter 2013 Financial Results
May 1, 2013
|
35.5 KB |
|
| |
EXTON, Pa., May 1, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced financial results for the first quarter of 2013. Net sales were $107 million for the first quarter ended March 31, 2013 as compared to $136 million in the comparative period of 2012. The decline in net sales quarter over quarter was driven by the decreas...
|
|
ViroPharma To Release 2013 First Quarter Financial Results On May 1, 2013
Apr 25, 2013
|
14.2 KB |
|
| |
EXTON, Pa., April 25, 2013 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) first quarter financial results for 2013 are expected to be released on Wednesday, May 1, 2013 before the open of the U.S. financial markets.
The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the...
|
|
Treatment With VP20621 (Non-Toxigenic Clostridium difficile; NTCD) In A Phase 2 Study Resulted In High Rates Of Colonization And Statistically Significant Reductions In Recurrence Of C. difficile Infection
Apr 22, 2013
|
23.2 KB |
|
| |
EXTON, Pa., April 22, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM), an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a nove...
|
|
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
Feb 27, 2013
|
36.4 KB |
|
| |
EXTON, Pa., Feb. 27, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the fourth quarter and year ended December 31, 2012.
In 2012, we:
Achieved $428 million in annual net product sales, highlighted by $327 million in Worldwide net sales of Cinryze® (C1 esterase inhibitor [h...
|
|
ViroPharma To Release 2012 Fourth Quarter And Full Year Financial Results On February 27, 2013
Feb 22, 2013
|
14.4 KB |
|
| |
EXTON, Pa., Feb. 22, 2013 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) fourth quarter and full year financial results for 2012 are expected to be released on Wednesday, February 27, 2013 before the open of the U.S. financial markets.
The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the s...
|
|
ViroPharma To Participate In Two Upcoming Healthcare Investor Conferences
Feb 11, 2013
|
14.3 KB |
|
| |
EXTON, Pa., Feb. 11, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the 2013 Leerink Swann Global Healthcare Conference at 11:30 AM ET on Thursday, February 14, 2013. The conference is being held at the Waldorf Astoria in Ne...
|
|
Sub-Group Analysis Of Data From Pediatric Patients With Hereditary Angioedema Published In The Journal Of Pediatrics
Jan 16, 2013
|
25.5 KB |
|
| |
EXTON, Pa., Jan. 16, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the publication of data demonstrating that use of Cinryze® (C1 esterase inhibitor [human]) in pediatric patients provided relief from symptoms of hereditary angioedema (HAE) attacks and reduced the rate of attacks. HAE is a rare, severely debilita...
|
|
ViroPharma Provides 2013 Outlook
Jan 7, 2013
|
21.2 KB |
|
| |
EXTON, Pa., Jan. 7, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will provide an overview of the company's business, including additional maribavir clinical trial data, during the 31st Annual J.P. Morgan Healthcare Conference. The presentation w...
|
|
ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2b Dose Ranging Combination Study for Subcutaneous Administration of Cinryze® (C1 esterase inhibitor [human]) With Hyaluronidase (rHuPH20)
Dec 19, 2012
|
22.0 KB |
|
| |
EXTON, Pa., Dec. 19, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics (Nasdaq: HALO) announced today that ViroPharma has initiated its Phase 2b double blind, multicenter, dose ranging study to evaluate the safety and efficacy of subcutaneous (SC) administration of Cinryze® (C1 esterase inhibitor [human)] i...
|
|
ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
Dec 12, 2012
|
15.7 KB |
|
| |
EXTON, Pa., Dec. 12, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced the launch of a new unbranded campaign focusing on moments lost to hereditary angioedema (HAE) attacks to raise awareness among physicians of the emotional and psychological burden of HAE on patients' lives. HAE is a rare, severely debilitating, life-th...
|
|
ViroPharma To Participate In Two December Healthcare Investor Conferences
Nov 29, 2012
|
14.1 KB |
|
| |
EXTON, Pa., Nov. 29, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Deutsche Bank dbAccess BioFest 2012 Conference at 9:00 AM ET on Monday, December 3, 2012. The conference is being held at the Four Seasons Hotel in Boston.
...
|
|
ViroPharma's Cinryze® (C1 Esterase Inhibitor [Human]) Prophylaxis Study Showed Safety Data of Escalating Doses in Patients With Hereditary Angioedema
Nov 13, 2012
|
20.8 KB |
|
| |
EXTON, Pa., Nov. 13, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced important data from an open-label, multicenter study to assess the safety, tolerability, and treatment effect of escalating doses of C1 INH-nf in patients with HAE who were not adequately controlled with 1000 U every 3 or 4 days. The results of this stu...
|
|
ViroPharma To Participate In Two November Healthcare Investor Conferences
Nov 8, 2012
|
14.1 KB |
|
| |
EXTON, Pa., Nov. 8, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 2012 Jefferies Global Healthcare Conference at 11:20 AM GMT (6:20 AM ET) on Thursday, November 15, 2012. The conference is being held at the Waldorf Hilton in ...
|
|
ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
Oct 25, 2012
|
35.6 KB |
|
| |
EXTON, Pa., Oct. 25, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the third quarter ended September 30, 2012.
Since June 30, 2012, we:
Achieved $91 million in quarterly net product sales, including $85 million in worldwide net sales of Cinryze;
Received FDA approval of th...
|
|
Health Canada Approves New Drug Submission for Cinryze™ (C1 inhibitor [human])
Oct 22, 2012
|
20.1 KB |
|
| |
EXTON, Pa., Oct. 22, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that Health Canada has granted a Notice of Compliance (NOC) and approved a New Drug Submission (NDS) for Cinryze™ (C1 inhibitor [human]). Approval of Cinryze was granted for routine prevention of angioedema attacks in adult and adolescents with h...
|
|
ViroPharma To Release 2012 Third Quarter Financial Results On October 25, 2012
Oct 18, 2012
|
14.2 KB |
|
| |
EXTON, Pa., Oct. 18, 2012 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) third quarter financial results for 2012 are expected to be released on Thursday, October 25, 2012 before the open of the U.S. financial markets.
The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During ...
|
|
ViroPharma Presents New Cinryze® (C1 Esterase Inhibitor [human]) Data On Site Of Care And Adherence At The 2012 Academy Of Managed Care Pharmacy Educational Conference
Oct 4, 2012
|
20.9 KB |
|
| |
EXTON, Pa., Oct. 4, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the results from an analysis of a patient-database involving Cinryze® (C1 esterase inhibitor [human]) demonstrating that ViroPharma's Path to Independence™ program, a self-administration training and support program for hereditary angioedema (...
|
|
ViroPharma And Halozyme Provide Update On Clinical Development Of Subcutaneous Cinryze® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20)
Sep 21, 2012
|
22.4 KB |
|
| |
EXTON, Pa. and SAN DIEGO, Sept. 21, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced today that the U.S. Food & Drug Administration (FDA) has provided guidance enabling ViroPharma to resume clinical studies of the subcutaneous administration of Cinryze in combination with rHuPH20. ...
|
|
ViroPharma To Host Analyst And Investor Seminar On September 21, 2012
Sep 18, 2012
|
19.6 KB |
|
| |
EXTON, Pa., Sept. 18, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today that the company will provide a live audio and slide webcast of its analyst and investor seminar, focusing on the company's commercial product projections and future growth opportunities on Friday, September 21, 2012. Lectures will be provided by a nu...
|
|
|